Excess Risk of Temporomandibular Disorder Associated With Cigarette Smoking in Young Adults by Sanders, Anne E. et al.
Excess Risk of Temporomandibular Disorder Associated with
Cigarette Smoking in Young Adults
Anne E. Sanders1, Gary D. Slade1, William Maixner2, Andrea G. Nackley2, Luda
Diatchenko2, Kunthel By3, and Vanessa E. Miller2
1Department of Dental Ecology, School of Dentistry, University of North Carolina at Chapel Hill
2Center for Neurosensory Disorders, University of North Carolina at Chapel Hill
3Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina
at Chapel Hill
Abstract
Evidence suggests that the effect of cigarette smoking on chronic pain is stronger in younger than
older adults. This case control study investigated whether age modified an effect of smoking on
temporomandibular disorder (TMD) in 299 females aged 18–60 years. It also investigated the
extent to which this relationship was explained by psychological profile, inflammatory response
and allergy. Cases were defined using the Research Diagnostic Criteria for Temporomandibular
Disorders based on clinical examination. Psychological profile was evaluated using standardized
instruments. Inflammatory response was evaluated with 11 cytokines isolated in plasma. History
of allergy conditions was self-reported. Odds ratios (OR) for the effect of smoking were calculated
using binary logistic regression. Stratified analyses and the likelihood ratio test examined effect
modification by smoking. Compared to non-smokers, ever smokers aged <30 years had higher
odds of TMD (OR =4.14, 95% CI: 1.57, 11.35) than older adults (OR =1.23, 95% CI: 0.55, 2.78)
(P (effect modification) =0.038). Adjustment for psychological profile, cytokines and history of
allergy-like conditions attenuated the effect by 45% to statistical non-significance. The main
finding was reproduced with secondary analyses of two nationally-representative surveys of adults
conducted in the U.S. and Australia.
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Introduction
Tobacco smoke plays a role in several chronic pain conditions.29, 41, 48, 52, 71 A meta-
analysis of the association between smoking and low back pain from 27 cross-sectional and
13 cohort studies showed that, compared to non-smokers, smokers had greater risk of pain.
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There was a dose-response relation in which greater exposure to tobacco was associated
with greater risk of pain.55 The 13 prospective cohort studies in this meta-analysis helped
clarify temporal ambiguity, showing that smoking preceded pain onset in current and former
smokers. Of particular interest was that the effect of smoking on pain incidence was greater
in younger than older adults.
Headache is another pain condition in which the effect of smoking is more pronounced at
younger age. The Head-HUNT Study, a Norwegian population-based study of 51,383 adults,
found an effect of smoking on headache was modified by age, peaking around 30 years and
then declining (P effect modification <0.0001).1 In a New Zealand birth cohort a two-fold
risk of headache due to smoking present in adolescence, was no longer apparent when the
cohort was aged 26 years.63
Three studies have examined smoking in temporomandibular disorder (TMD)36, 65, 66 but
none has examined whether its effect differs by age. Accounting for smoking is important in
TMD research not only because of smoking’s potential causal role, but also because
smoking may account for effects of other TMD risk factors including perceived stress,
anxiety, and depression. 10, 12, 35, 49, 50
Psychological stress is well recognized for its relationship with TMD. Less well investigated
are the roles of allergy and inflammation. This is surprising given that allergy is comorbid
with several idiopathic pain conditions including fibromyalgia,8 low back pain,24 headache,2
vulvodynia 21 and irritable bowel syndrome.61 In addition elevated levels of inflammatory
cytokines are associated with headache,27 fibromyalgia6, 8 and irritable bowel syndrome.5
One possible mediator is monocyte chemoattractant protein-1 (MCP-1). This chemokine
induces histamine release from basophils7 and contributes to the pathogenesis of allergic
disorders. 23, 69 MCP-1 concentration was 2.3-fold higher in synovial fluids of TMD cases
than non-cases, although differences failed to reach statistical significance.44
Whether young smokers are more susceptible than nonsmokers and older adults to pain
mediated by an inflammatory or allergy pathway is unknown. What is established is that
smoking is associated with the production of pro-inflammatory cytokines and inhibition
anti-inflammatory cytokines. Smoking increases sensitization to allergens 26 and facilitates
permeability of the respiratory epithelium.17 Serum immunoglobulin E (IgE) levels are
higher in smokers than non-smokers60 and IgE levels decrease dramatically with age. The
age-related reduction is especially noticeable in atopic females, until 35 years after which
further age-related declines are not apparent.4 Taken together, the findings imply that
smoking may influence pain either through allergic or inflammatory pathways, or both.
To clarify these relationships, this study tested whether age modified a relation between
smoking and TMD. We hypothesized that an effect of smoking on TMD was stronger in
younger adults. If confirmed, the second aim was to quantify the extent to which
psychological vulnerability, allergy-related conditions, and plasma cytokine levels
attenuated the smoking-related effect.
Materials and Methods
This study was approved by the Biomedical Institutional Review Board of the University of
North Carolina at Chapel Hill (UNC-CH). Written informed consent was obtained from all
study participants.
Study design and recruitment
Data for this analysis were from a case-control study of risk factors for chronic TMD.
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All study participants were female, aged between 18 and 60 years and self-identified as
Caucasian. Sampling was limited to females because prevalence of TMD is greater in
females than males. The rationale for limiting inclusion to a single racial group was to
simplify interpretation of genetic findings since one objective of the study is to investigate
genetic risk factors for TMD. All study participants were recruited from the Central North
Carolina community with the use of fliers, mass informational emails sent to the UNC-CH
population, and advertisements in local newspapers, radio and at the Orofacial Pain Clinic at
the UNC-CH School of Dentistry between 2005 and 2009.
All potential participants were screened by a telephone interview to exclude those with
diagnoses of any one of diabetes, kidney disease, heart failure, chronic respiratory disease,
epilepsy or seizure disorder, or high blood pressure not controlled with medication. Also
excluded were those who were pregnant, nursing, undergoing orthodontic treatment, renal
dialysis, radiation or chemotherapy as well as persons with trauma or surgery on the head,
face or neck within the last six months.
A medical history was recorded for all subjects prior to a clinical examination. Examinations
were performed by one of ten examiners trained in the examination protocol and calibrated
for the reliability and validity of their diagnostic decisions every six months. Cases were
persons who met Research Diagnostic Criteria for Temporomandibular Disorders (TMD)15
for myalgia, arthralgia or both, based on a In summary, cases were people who reported a
six-month history of pain in the temporomandibular structures, with at least 5 days of such
pain in the month preceding the examination and where examiners found at least three
muscle groups in the temporomandibular region that were tender to palpation or jaw
maneuver. The threshold of six months was chosen to be consistent with the classification
for chronic pain for research purposes described in the IASP Task Force on Taxonomy.38
Controls reported no history of orofacial pain within the preceding six months and no prior
diagnosis for TMD. Additionally, their examination confirmed that they did not have
arthralgia or myalgia.
Smoking status
Lifetime smoking status was evaluated with the question widely used in major US
population surveys including the National Health Interview Survey (NHIS), the National
Health and Nutrition Examination Survey (NHANES) and the Behavioral Risk Factor
Surveillance Survey (BRFSS): Have you smoked at least 100 cigarettes in your entire life?”
Those with a negative response were classified as lifetime non-smokers. Those with an
affirmative response were further classified as current or former smokers.
Allergy-related conditions
A medical history questionnaire presented a list of conditions against which participants
checked “Yes” if they had ever had the condition; otherwise they checked “No”. Conditions
included dermal mucocutaneous conditions (skin rashes), respiratory conditions (sinus
trouble, allergies or hives) and any use of antihistamine medication.
Cytokines
Cytokines are small intracellular regulatory proteins that play a major role in immune
response as well as cell growth and tissue repair. 18, 40, 53 Peripheral blood samples were
collected and plasma was isolated using multiplex technology to measure 11 cytokines
(R&D Systems; Minneapolis, MN). Cytokines included on the multiplex panel were:
vascular endothelial growth factor (VEGF); fibroblast growth factor (FGF); interleukin-1
receptor antagonist (IL-1Ra); monocyte chemoattractant protein-1 (MCP-1); interleukin-6
(IL-6); interleukin (IL-8); epithelial neutrophil-activating protein 78 (ENA-78), tumor
Sanders et al. Page 3













necrosis factor-alpha (TNFα), macrophage inflammatory protein 1 alpha (MIP-1α),
granulocyte-colony stimulating factor(G-CSF) and thrombopoietin (TPO). Concentrations of
the 11 cytokines were standardized and each was tested for its strength of their association
with TMD in logistic regression. Eight of these had significantly elevated concentrations in
TMD cases compared with controls (P<0.05). Those not significantly associated with TMD
were FGF, G-CSF, TNFα and IL-6. For the purpose of this analysis, we selected the two
cytokines in which odds of TMD increased by ≥50% per standard deviation increase in
cytokine concentration. One cytokine was IL-1Ra; a potent inhibitor of two pro-
inflammatory cytokines – IL-1alpha and IL-1beta. The other, MCP-1, a chemokine, serves
multiple functions including a role in the pathophysiology of allergy and activation of
histamine release in basophils. 3, 43
Psychological measures
We classified psychological vulnerability with three factors: psychological stress, trait
anxiety and history of depression. Psychological stress was evaluated with the 10-item
Perceived Stress Scale (PSS)11 that measures the extent to which respondents consider their
lives to have been unpredictable, uncontrollable, and overloaded during the preceding
month. Responses were made on a five-point scale of frequency ranging from “never” to
“very often”. Positive items were reversed scored before all responses were summed to yield
an overall scale score where higher scores denote greater psychological distress. The 20-
statement trait anxiety subscale of the Spielberger State and Trait Anxiety Inventory for
adults58 was administered to measure this stable, enduring component of anxiety. Responses
were made on a four-point scale of frequency ranging from “not at all” to “very much so”. A
single question in the medical history questionnaire asked whether or not participants had
ever taken antidepressant medication (yes/no). This question serves as a proxy for lifetime
history of depressive symptoms. Given that our interest was the study of chronic TMD, we
were less interested in existing clinical depressive symptoms than in lifetime history of
treatment for depression because risk of developing chronic TMD is likely to be influenced
by exposures over a long period.
Statistical analyses
Analysis was guided by a directed acyclic graph (Figure 1). For young adults the graph
depicts an indirect effect of cigarette smoking on TMD that is mediated by an inflammation
or allergy pathway. The same pathways for older adults are depicted to bypass smoking. A
binary logistic regression model was used to assess the association between smoking and
TMD. Odds ratios were calculated as estimates of the strength of association and 95%
confidence intervals for the odds ratios signified the precision of the odds ratio estimates.
Associations were deemed statistically significant when the 95% confidence interval
excluded the null value of 1.0. To test the study hypothesis that the association between
smoking and TMD was modified by age, we dichotomized age (<30 versus ≥30 years) after
fully exploring the age and TMD relationship. For descriptive purposes, odds of TMD were
compared between tertiles of cytokine concentrations and scores for perceived stress and
trait anxiety. In multivariable analysis these continuous variables were standardized so that
the resulting odds ratios estimated the relative change in odds of TMD associated with one
standard deviation of change in the continuous measure. Decisions regarding confounding
were based on 1) whether the covariate is associated with both smoking and TMD case
status, and 2) whether inclusion of the covariate produces a change of ≥10% in in the odds
ratio for the association between smoking and TMD.
Because only a small number of participants were current smokers (19 cases and 9 controls),
analyses of smoking combined former and current smokers into a single group labeled “ever
smokers”. To investigate allergic conditions, a composite variable was computed that
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summed the number of allergic conditions reported to yield a possible range from zero (no
allergic conditions) to four allergy conditions.
To test the second aim, odds of TMD was modeled through a sequence of four logistic
regression models. Model 1 contained dichotomized smoking, dichotomized age, and their
interaction term. Model 2 added the composite variable for allergy-related conditions. Model
3 added the cytokines, and Model 4 added the psychological variables. The purpose of this
sequential model building was to quantify the extent to which each model attenuated the
odds ratio for smoking in each age stratum. This would determine whether the added
variables act as mediators between smoking and TMD in early adulthood. To illustrate how
adjustment for covariates altered age-specific associations between smoking and TMD in
this sample, the predicted proportion of TMD cases was calculated using parameter
estimates from Model 1 (unadjusted) and Model 4 (fully-adjusted), and the proportions were
plotted. While the predicted probabilities are valid estimates for this study sample, they
should not be interpreted as population estimates of prevalence because the overall
proportion of cases was specified by the study design that purposefully selected
approximately equal numbers of cases and controls.
To test the generalizability of an age effect on the smoking-TMD relationship, secondary
analyses were undertaken using two population-based, nationally representative
epidemiological surveys of adults in the United States and Australia. These surveys were the
2007-2009 National Health Interview Survey (NHIS) and the 2004-2006 National Survey of
Adult Oral Health in the U.S. and Australia.57 Orofacial pain was self-reported in both
surveys. Analyses were limited to females for the purpose of comparison with this study.
For the NHIS dataset, orofacial pain symptoms were evaluated with the question, “During
the past three months, did you have facial ache or pain in the jaw muscles or the joint in
front of the ear?” Response categories were Yes/No/Don’t know. We estimated the
prevalence of facial pain for various subpopulations that are defined by the cross-
classification of age and smoking status. Since the collection of NHIS data is based on a
multistage complex survey design and since our focus was confined to adults, we used the
adult sampling weights to obtain unbiased estimates of facial pain prevalence and valid
standard errors. Specifically, we combined data sets from 2007 to 2009 and divided the
sampling weights by three. Adults with missing facial pain response were omitted from
analyses.
In the Australian national survey, prevalence of orofacial pain symptoms was determined
from seven screening questions that had been validated in a Canadian study.34 Three
questions asked about pain in the jaws, jaw joint or pre-auricular region and four questions
addressed jaw function disturbance such as difficulty opening the mouth wide and freely.
Responses of “yes” or “no” were recorded for each symptom in a self-completed
questionnaire. The case definition required one or more affirmative response to the pain
questions and at least one affirmative response to the jaw function disturbance questions. In
data analysis, survey estimation commands corrected the standard errors of estimates by the
Taylor series linearization method to take account of the complex survey design.
Data were analyzed in STATA I/C statistical software, version 11.1 IC (Stata Corporation,
Texas) and results reported for 133 cases and 166 controls with complete data.
Results
The mean age of cases was 36.4 years (95% CI=34.3, 38.6) compared with 28.7 years for
controls (95%=27.1, 30.3). The older category of age was associated with greater odds of
TMD (Table 1). One third (37%) of cases reported having heard about the study through the
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UNC orofacial pain clinic; the remainder of cases and nearly all controls (98%) responded to
advertisements and other methods of recruitment.
Compared to lifetime non-smokers, current smokers had three times the odds of TMD (odds
ratio [OR] =3.33, 95%CI 1.44, 7.70) while former smokers had twice the odds. Higher
concentrations of IL-1Ra and MCP-1 were associated with higher odds of TMD in a dose-
response relation. Likewise perceived stress and trait anxiety were associated with TMD in a
dose-response relation. All four allergy-related conditions were positively and strongly
associated with TMD. When the allergy-related conditions were summed, 16.7% of controls
reported having all four conditions compared with 83.3% of TMD cases (Chi2, (4df) =
48.901, P< 0.001).
Examination of the stratum-specific odds ratios (Table 2) revealed that compared to lifetime
non-smokers, ever smokers had higher odds of TMD (OR =4.14, 95% CI: 1.57, 11.35) in the
aged 18 to 29 stratum but the relationship was non-significant in the older stratum. (OR
=1.23, 95% CI: 0.55, 2.78) The Breslow-Day test for homogeneity (P= 0.038) confirmed
that the smoking effect differed significantly across age strata.
Greater concentrations of IL-1Ra and MCP-1, a lifetime history of skin rashes or sinus
trouble were associated with older age. Smoking was more frequent in older than younger
people (Table 3). Among those who had ever smoked relative to never smoked, we observed
higher concentrations of cytokines, greater perceived stress and greater use of antidepressant
medication, history of allergies, skin rashes sinus trouble and antihistamine use.
Mean IL-1Ra concentrations did not differ between subjects with and without history of
allergy-related conditions (Table 4). However mean MCP-1 levels were significantly higher
in subjects with history of an allergy-related condition.
The effect modification of age on the smoking and TMD relationship presented in Model 1
(Table 5) was attenuated following adjustment for allergy-related conditions in Model 2.
After additional adjustment for the cytokine mediators in Model 3 and the psychological
variables in Model 4 the association between smoking and TMD in people aged <30 years
was rendered non-significant (OR = 2.28, 95%CI = 0.81, 6.43). Furthermore, the interaction
between smoking and age was statistically non-significant. This attenuation of the smoking
effect is depicted in Fig. 2a (unadjusted) and 2b (adjusted). Here the unadjusted findings
from Model 1 show a lack of overlap in 95% confidence intervals for proportion of cases
between smokers and non-smokers in the young stratum (Fig 2a). However, 95%CIs overlap
(Fig 2b) in this younger age group when the estimates are adjusted using the variables listed
for from Model 4 in Table 5.
Secondary analyses of the National Health Interview Survey (2007-2009) in the United
States and the National Survey of Adult Oral Health (2004-2006) in Australia confirmed a
relationship between smoking and orofacial pain in females (Figures 3a and 3b). Again the
effect was strongest in younger versus older females, although the threshold age at which
smoking ceased to have an effect appeared to be older in these national surveys than in our
case control study. The effect modification was significant in the United States (P<0.001)
but not in Australia (P=0.811).
Discussion
To the best of our knowledge this is the first study to have examined the relationship
between smoking and TMD in age-specific strata. The key finding was that a history of
cigarette smoking was strongly associated with TMD, but only among young adults.
Specifically in this case control study, smokers aged 18 to 29 years, had four times the odds
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of having TMD when compared with 18-29 year old non-smokers. In adults aged 30 to 60
years, TMD case status had no association with smoking status.
The second major contribution of this study is the first reported finding of an association
between any history of allergy-related conditions and TMD. We showed the effect of
smoking on TMD in young adults was attenuated 20% after adjustment for four allergy-
related conditions. The effect was further attenuated 45% to statistical non-significance after
additional adjustment for cytokines and psychological profile.
Our finding that age modified the effect of smoking on TMD is in accordance with previous
studies of low back pain. Pooled estimates from a meta-analysis showed that the association
between current smoking and incident low back pain was stronger in adolescence (OR
=1.82, 95% CI =1.12, 2.33) than in adults (OR=1.16; 95% CI= 1.02, 1.32).55
Our results also build on evidence of an association between allergy and chronic pain. In the
third US National Health and Nutrition Examination Survey, adults aged 20-39 with any
history of asthma, hay fever and other allergies were 50% more likely to report low back
pain than 20-39 year olds without allergies.24 Elsewhere a case control study of vulvodynia
showed that odds of the condition were elevated between 2.0-fold to 2.5-fold in women with
a history of any of seasonal allergies, reactions to insect bites or hives. In that study the self-
reported allergy conditions preceded the first report of vulvar pain.21 The authors suggested
that an altered immune-inflammatory response to environmentally induced allergic reactions
was a possible explanatory mechanism. And in the 51,383 Head-Hunt Study participants,
headache was 1.5 times more likely among those with asthma, asthma related symptoms,
hay fever and chronic bronchitis.2 Based on their findings from a population-based study,
Hurwitz and Morgenstern hypothesized that hypersensitivity reactions evoke dysfunctional
reactivity of the hypothalamic–pituitary–adrenal axis to psychological stress with
consequences for chronic pain.24 We found that an inflammatory response and allergic
conditions had independent effects on odds of TMD in young adult smokers (Model 3, Table
4). In young adults, adjustment for inflammation as indexed by two cytokines, a history of
allergy-related conditions, and psychological profile fully accounted for the effect of
smoking on TMD.
In line with results from previous clinical studies, 16, 45, 44, 46 we found that levels of the
cytokines MCP-1 and IL-1Ra were associated with increased odds of TMD. MCP-1 is a
chemotactic cytokine expressed in a variety of cell types, including leukocytes in the
periphery 70 and neurons in the central nervous system 67. IL-1Ra is member of the
interleukin-1 cytokine family that is largely expressed in macrophages and epithelial cells 22
as well as in brain. 32 IL-1Ra binds the proinflammatory cytokines interleukin-1α (IL-1α)
and interleukin-1β (IL-1β), thus inhibiting their activity. 14 Studies in animal models
demonstrate that expression of both MCP-1 and IL-1Ra is strongly upregulated following
injury or inflammation. 25, 37, 64, 67 A mechanistic role for MCP-1 in chronic pain is
supported by recent studies showing that MCP-1 is able to excite sensory neurons. 67 While
a mechanistic role for the anti-inflammatory cytokine IL-1Ra in chronic pain is less clear, its
synthesis and release is stimulated by the proinflammatory cytokine IL-1. Kinetic studies
have demonstrated that the balance between IL-1Ra and IL-1 production is dependent upon
the phase of the inflammatory response. 59 Thus, IL-1Ra may be viewed as a marker of
IL-1, which is deemed a prototypical proinflammatory cytokine well known for its ability to
activate and sensitize nociceptors 28 as well as drive HPA-related stress responses. 19
Collectively, these results suggest that MCP-1 and IL-1Ra/IL-1 inflammatory pathways
contribute to TMD.
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One explanation for why the smoking and TMD relationship was found only in young adults
is that one or more of the explanatory factors operate differently between young and older
individuals. Support of this supposition comes from a study of the Swiss adult population,
where odds of being atopic decreased by 21.0% on average with every 10-year increase in
age.68
Little is known about exposure to tobacco smoke and IL-1Ra and MCP-1 concentrations in
humans. One report of a positive association between smoking and plasma concentration of
IL-1Ra in healthy subjects 13 conflicted with the finding of higher IL-1ra concentrations in
non-smokers than smokers.39 In the periodontal literature a comparison of gingival crevice
fluid IL-1ra concentrations in smokers and non-smokers, found smokers had significantly
higher IL-1ra concentrations in healthy periodontal sites than non-smokers. However in
subjects with deep bleeding periodontal sites, smokers had significantly lower IL-1ra
concentrations than non-smokers.51 A recent experimental study showed that cigarette
smoking and nicotine significantly induced MCP-1 expression in pancreatic ductal
adenocarcinoma cells.30 In humans, MCP-1 concentration was significantly elevated in
healthy smokers compared with healthy former smokers.9
The active ingredients in tobacco smoke that alter pain perception are not fully understood,
but it is generally assumed that nicotine is the primary substance that modifies pain
perception. The effects of nicotine on pain perception are complex (for a review see Shi et,
al., 2010).54 Experimental studies that use brief noxious stimuli following the ingestion of
nicotine provide evidence that nicotine has analgesic properties. Chronic exposure to
tobacco smoke leads to changes in pain perception such that smokers deprived of nicotine
show greater sensitivity to pain evoking stimuli.42, 56 In the postoperative pain setting, the
administration of nicotine produces analgesia in nicotine naïve participants and produces
little or no analgesic effect in smokers.20, 62 The chronic exposure to nicotine can induce
biological states that produce hyperalgesia and dependency similar to that seen with the
chronic exposure to opioids when nicotine levels are acutely reduced. We speculate that the
diminished effect of smoking at ages older than 30 results from a diminished effect of
smoking on the production of proinflammatory substances, which diminishes the likelihood
of developing post-nicotine exposure hyperalgesic states.
The risk of chronic TMD in young former or current smokers was more than four times as
high compared with older adults who had never smoked. Simultaneous adjustment for
psychological profile, cytokines and allergy conditions approximately halved this effect and
rendered the effect of smoking in young adults statistically non-significant showing these to
be explanatory factors for excess risk. Nonetheless in the fully adjusted model, allergy
conditions, interleukin-1 receptor antagonist and trait anxiety score remained significantly
associated with TMD in young adults showing these to be independent risk indicators
beyond the effects of tobacco. These findings highlight noteworthy age-related differences.
For instance, ever smokers were twice as likely as life-time non-smokers to perceive high
psychological distress but this effect was evident only in young adults. In addition, ever-
smokers were twice as likely as non-smokers to have a history of allergy conditions and to
use antihistamines, and again these effects were more pronounced in young versus older
adults. Furthermore ever smokers had four times the odds of chronic TMD than lifetime
non-smokers, but only among young adults. This consistency of evidence suggests that the
relationships between smoking, psychological stress, allergy and TMD risk differ on the
basis of age; indeed these case control results formally confirmed that age significantly
modified the smoking and TMD relationship. Of these risk indicators in young adults,
smoking may be the most easily modified and smoking cessation may have long-term
benefits for inflammatory function, psychological health and conditions such as allergic
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rhinitis 33 and urticaria.31 However it is not known whether smoking cessation might negate
any analgesic effects of nicotine on TMD pain.
Strengths of this study were use of the well-validated Research Diagnostic Criteria for
determining TMD case status and the diverse dataset that included psychological
instruments and cytokines. Another major strength was that we were able to reproduce our
findings in two large national surveys with representative samples of female adults. The
self-reported nature of TMD symptoms in these national surveys inevitably results in over-
estimation or under-estimation of TMD prevalence. Despite this misclassification, the
relationship was sufficiently strong to replicate our case control findings, which
strengthened this study’s external validity.
Nonetheless, several possible limitations should be considered when interpreting our study
findings. This case-control study design and the cross-sectional design of the national survey
did not establish a temporal sequence between smoking and onset of TMD. It is plausible
that some people might have begun to smoke as a consequence of developing TMD
symptoms. Moreover anxiety and psychological stress may make smoking cessation efforts
more difficult, as smokers with TMD may rely on tobacco to elevate mood and relieve
comorbid depressive symptoms. This “reverse causation” might account for some of the
observed association between smoking and TMD. However, the evidence from prospective
cohort studies of other chronic pain conditions suggests that the predominant effect is in the
expected causal direction.55
The degree to which TMD cases and controls were misclassified during examination is
unrelated to the exposures of interest in this study (tobacco use, psychological profile,
cytokines, allergy conditions). Therefore any misclassification of case status would produce
non-differential bias, which does not pose a concern to the strength or direction of
associations reported in this study. The only adverse impact of misclassification is increased
variance (i.e. widened 95%CIs) around our estimates. A related concern with case-control
studies is whether controls are selected from the same source population that gives rise to
the cases.47 Yet, most controls heard about the study through the same methods reported by
nearly all cases, suggesting that the majority of cases and controls came from the community
at large.
Due to the relatively small number of current smokers, we limited the analysis of effect
modification to a binary exposure measure. Hence, the risk of TMD associated with
smoking cannot be attributed solely to elevated concentrations of nicotine or other
substances inhaled in cigarette smoke because there is no such elevation in former smokers.
Yet, the bivariate findings in Table 1 show that the odds ratio for TMD is greater in current
smokers than in former-smokers. This suggests that exposure to tobacco itself confers an
additional risk for TMD, in addition to behavioral characteristics or other antecedents of
smoking behavior. The small number of current smokers in this study reduces precision of
estimates making interpretation of the strength of the smoking and TMD relationship more
difficult.
Finally, our measures of allergy-related conditions were taken by convenience from the
medical history questionnaire and were not planned in advance. However in future analyses
we will examine IgE levels in stored blood. We used history of antidepressant medication as
a marker of psychological profile. This may introduce misclassification as chronic pain
sufferers are sometimes prescribed antidepressants for pain control as well as fatigue, or
sleep disturbances.
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This study has shed light on a complex interplay of allergy, cytokines, and smoking in a case
control study of chronic TMD. Understanding the mechanisms underlying these
relationships can best be addressed in large prospective studies of chronic TMD pain.
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This study showed that smoking was associated with TMD risk in females, but only in
young adulthood. It replicated this finding in two nationally representative surveys of
females in the U.S. and Australia. Findings may alert clinicians to recognize that smoking
is a concern for TMD in younger female patients.
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Directed acyclic graph depicting the pathway between smoking and temporomandibular
disorder (TMD) in young (aged <30 years) and older adults defined as psychologically
vulnerable (on the basis of psychological stress and trait anxiety scores and a history of
antidepressant medication usage).
The solid black line represents the proposed pathway for young adults. It passes through
tobacco smoking to inflammation (cytokines IL-1Ra and MCP-1) and allergy (self-report of
skin rashes, sinus trouble, allergies or hives, antihistamine use). The dashed gray line
represents the causal pathway for older adults, which bypasses smoking. The graph assumes
no unmeasured confounders given control for measured variables.
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Illustration of interaction between age and smoking with no adjustment for covariates.
Parameter estimates from Model 1 of Table 5 were used to calculate predicted proportions
of TMD cases within this sample of 299 people in Chapel Hill, USA.P-value for
interaction=0.039)
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Illustration of interaction between age and smoking with adjustment for covariates shown in
Model 4 of Table 5: sum of allergies, Interleukin-1 receptor antagonist and monocyte
chemotactic protein-1 concentrations, perceived psychological stress, trait anxiety and
lifetime history of antidepressant medication usage. Parameter estimates from Model 5 of
Table 5 were used to calculate predicted proportions of TMD cases within this case-control
sample of 299 people in Chapel Hill, USA. (P-value for interaction=0.118)
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Relationship between smoking status and facial pain across age strata among females living
in the United States. Prevalence is the percentage of subjects who answered affirmatively to
the question, “During the past three months, did you have facial ache or pain in the jaw
muscles or the joint in front of the ear?” Data are nationally representative estimates for
female participants aged 18 years and older in the National Health Interview Survey
2007-2009 (n=40,337). P value for the age*smoking interaction <0.001
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Relationship between smoking status and orofacial pain symptoms across age strata among
females living in Australia. Prevalence of orofacial pain symptoms was assessed in a self-
administered questionnaire with seven screening questions. Three questions asked about
pain in the jaws, jaw joint or pre-auricular region and four questions addressed jaw function
disturbance such as difficulty opening the mouth wide and freely. The case definition used
in this study required one or more affirmative response to the three pain questions and at
least one affirmative response to the four jaw function disturbance questions. Data are
nationally representative estimates for females in the National Survey of Adult Oral Health
2004-2006 (n=2,461). P value for the age*smoking interaction = 0.8109
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Table 2
Relationship of cigarette smoking exposure to TMD (odds ratio [OR], 95% confidence interval [95% CI]),
stratified by age.
<30 years ≥30 years
OR 95% CI OR 95% CI
Ever smoker 4.14 1.57, 11.35 1.23 0.55, 2.78
Lifetime non-smoker Ref Ref
Breslow-Day test of homogeneity, P= 0.038
95% confidence interval is from the exact method for contingency tables
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